NMDP认识到，尽管造血干细胞移植（HSCT）和其他细胞疗法取得了进展，并不是所有的病人都能得到公平的治疗,结果差距依然存在。本文探讨了NMDP的最新工作，通过变革性临床研究加速进展并扩大对更多患者的访问，特别是在使用不匹配的无关供体进行HSCT时。
NMDP recognizes that despite advances in hematopoietic stem cell transplantation (HSCT) and other cell therapies, not all patients have equitable access to treatment, and disparities in outcomes remain. This paper explores the recent work of NMDP to accelerate progress and expand access to more patients through transformative clinical research, particularly in the use of mismatched unrelated donors for HSCT.
PDF(Pubmed)